<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Obesity Management • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Obesity Management • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/obesity management/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/obesity management/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="obesity-management" tabindex="-1">obesity management</h1>
<ul>
<li>related: <a href="/wiki/notes/Endocrine/">Endocrine</a></li>
<li>tags: #endocrine</li>
</ul>
<hr>
<!-- obesity management --> 
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/image-20200717143334032.png" alt=""></p>
<p>This patient has failed to improve with an adequate  trial of dietary modification. In addition, she has continued to gain  weight and now meets the definition of <strong>obesity</strong> (BMI &gt;30 kg/m2). In light of the risk of obesity-related complications, pharmacologic therapy is indicated.</p>
<h2 id="initial-medication-options-for-patients-with-obesity-are-listed-in-the-flow-chart.-orlistat-inhibits-pancreatic-lipases%2C-resulting-in-decreased-fat-absorption.-it-is-frequently-chosen-as-a-first-line-drug-due-to-its-excellent-safety-profile-and-choice-of-low-dose-(over-the-counter)-and-high-dose-(prescription)-options.-however%2C-orlistat-is-associated-with-significant-gastrointestinal-side-effects-(eg%2C-diarrhea%2C-bloating%2C-fecal-incontinence)%2C-and-some-patients-may-elect-to-start-with-another-medication." tabindex="-1">Initial medication options for patients with obesity are listed in the flow chart. <strong>Orlistat</strong> inhibits pancreatic lipases, resulting in decreased fat absorption. It is frequently chosen as a first-line drug due to its excellent safety  profile and choice of low-dose (over-the-counter) and high-dose  (prescription) options. However, orlistat is associated with  significant gastrointestinal side effects (eg, diarrhea, bloating, fecal incontinence), and some patients may elect to start with another  medication.</h2>
<p>This patient's presentation is consistent with adverse effects from the anti-obesity medication orlistat.  Orlistat is used for long-term treatment of obesity in patients with body mass index &gt; 30 kg/m2<strong>or</strong> &gt; 27 kg/m2 with comorbidities (eg, diabetes, dyslipidemia, hypertension).  The drug inhibits pancreatic lipase to alter fat digestion, decrease fat absorption, and increase fecal fat excretion.  As a result, patients with diet fat &gt; 30% of total calories can develop symptoms similar to <strong>fat malabsorption</strong> disorders (eg, flatus, fecal incontinence, abdominal distension).  A <mark>low-fat diet</mark> (&lt; 30% total fat calories) can reduce these symptoms.</p>
<p>Orlistat can also decrease absorption of fat-soluble vitamins, and patients should take a <mark>daily multivitamin</mark>.  Orlistat-induced fat malabsorption can also increase intestinal calcium binding, which leads to decreased available calcium to bind oxalate.  This leads to increased oxalate absorption, increased urinary oxalate excretion, and possible <strong>calcium oxalate stones</strong>.  As a result, orlistat should not be used in patients with history of calcium oxalate stones.</p>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        <nav class="toc" >
        <ul><li><a href="#initial-medication-options-for-patients-with-obesity-are-listed-in-the-flow-chart.-orlistat-inhibits-pancreatic-lipases%2C-resulting-in-decreased-fat-absorption.-it-is-frequently-chosen-as-a-first-line-drug-due-to-its-excellent-safety-profile-and-choice-of-low-dose-(over-the-counter)-and-high-dose-(prescription)-options.-however%2C-orlistat-is-associated-with-significant-gastrointestinal-side-effects-(eg%2C-diarrhea%2C-bloating%2C-fecal-incontinence)%2C-and-some-patients-may-elect-to-start-with-another-medication.">Initial medication options for patients with obesity are listed in the flow chart. Orlistat inhibits pancreatic lipases, resulting in decreased fat absorption. It is frequently chosen as a first-line drug due to its excellent safety  profile and choice of low-dose (over-the-counter) and high-dose  (prescription) options. However, orlistat is associated with  significant gastrointestinal side effects (eg, diarrhea, bloating, fecal incontinence), and some patients may elect to start with another  medication.</a></li></ul>
      </nav>
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Endocrine/" class="peer">Endocrine</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="endocrine" tabindex="-1">Endocrine</h1>
<ul>
<li>related: <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<h2 id="mksap" tabindex="-1">MKSAP</h2>
<ul>
<li><a href="/wiki/notes/Disorders%20of%20Glucose%20Metabolism/">Disorders of Glucose Metabolism</a></li>
<li><a href="/wiki/notes/Disorders%20of%20the%20Pituitary%20Gland/">Disorders of the Pituitary Gland</a></li>
<li><a href="/wiki/notes/Disorders%20of%20the%20Adrenal%20Glands/">Disorders of the Adrenal Glands</a></li>
<li><a href="/wiki/notes/Disorders%20of%20the%20Thyroid%20Gland/">Disorders of the Thyroid Gland</a></li>
<li><a href="/wiki/notes/Reproductive%20Disorders/">Reproductive Disorders</a></li>
<li><a href="/wiki/notes/Transgender%20Hormone%20Therapy%20Management/">Transgender Hormone Therapy Management</a></li>
<li><a href="/wiki/notes/Calcium%20and%20Bone%20Disorders/">Calcium and Bone Disorders</a></li>
</ul>
<h2 id="pituitary" tabindex="-1">Pituitary</h2>
<ul>
<li><a href="/wiki/notes/pituitary%20adenoma/">pituitary adenoma</a></li>
<li><a href="/wiki/notes/inappropriately%20normal%20TSH%20could%20be%20sign%20of%20central%20hypothyroidism/">inappropriately normal TSH could be sign of central hypothyroidism</a></li>
<li><a href="/wiki/notes/pituitary%20apoplexy/">pituitary apoplexy</a></li>
<li><a href="/wiki/notes/MEN/">MEN</a></li>
<li><a href="/wiki/notes/hyperprolactinemia/">hyperprolactinemia</a></li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
